Every Form 4 that IN8bio, Inc. (INAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8BIO, INC. director Emily Fairbairn reported an indirect transfer of common stock. On May 27, 2026, an entity associated with her made a bona fide gift of 724,637 shares of common stock at $0.00 per share to a 501(c)(3) charitable foundation. After this gift, she continued to report indirect holdings of 923 shares through the Malcom and Emily Fairbairn 2010 CRUT and 3,044 shares through Valley High Limited Partnership, while the Roth IRA account that made the gift reported no remaining shares.
IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.
The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.
IN8BIO director Greenwood Luba received a stock option grant for 22,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. One-twelfth of the shares vest monthly starting June 9, 2026, with full vesting at the next annual stockholders’ meeting if service continues.
IN8BIO, INC. executive Lawrence Lamb, EVP and CSO, received an employee stock option grant covering 54,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. After this grant, Lamb holds options for 54,000 shares directly.
According to the vesting terms, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to Lamb continuing to provide service through each vesting date.
IN8BIO, INC. director Emily Fairbairn received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in 12 equal monthly installments starting on June 9, 2026 and will in any case be fully vested on the date of the company’s next annual meeting of stockholders, subject to her continued service. These options expire on May 9, 2036, and following this grant she holds 22,000 stock options directly.
IN8bio, Inc. reported that its Chief Financial Officer, Patrick McCall, received an employee stock option grant for 56,250 options to buy common stock at an exercise price of $1.58 per share. Following this grant, he holds 56,250 derivative securities directly.
The option vests in four equal parts, with 25% of the shares vesting on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as he continues providing service through each vesting date. The option expires on May 9, 2036.
IN8BIO, INC. director Corinne Epperly received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036, and represent a compensation-related award rather than an open-market trade.
One twelfth of the options vest in equal monthly installments starting on June 9, 2026, with full vesting no later than the company’s next annual meeting of stockholders, as long as she continues providing service through each vesting date.
IN8BIO, INC. reported that President and COO Kate Rochlin received a grant of employee stock options covering 60,000 shares of common stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036.
These compensation-related options were awarded with no cash paid by the executive at grant. According to the vesting schedule, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as she continues providing service through each date. After this grant, she holds options for 60,000 underlying shares directly.
IN8BIO, INC. director Peter C. Brandt received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in equal monthly installments over 12 months starting on June 9, 2026, and any unvested portion becomes fully vested on the date of the company’s next annual stockholder meeting, subject to continued service. Following this grant, Brandt holds 22,000 stock options directly.
IN8BIO, INC. director Jeremy R. Graff received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $1.5800 per share and expire on May 9, 2036. One-twelfth of the options vest monthly starting June 9, 2026, or they become fully vested on the date of the company’s next annual stockholder meeting if he continues providing service.
IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO. On February 4, 2026, he received 72,000 employee stock options with a $1.96 exercise price, all held directly. Twenty-five percent vest on February 4, 2027, with the remaining options vesting in 36 equal monthly installments, contingent on his continued service.
IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award. On February 4, 2026, the CFO received an employee stock option to purchase 75,000 shares of common stock at an exercise price of $1.96 per share.
These options were awarded at no cost and are held directly. Twenty-five percent of the shares vest on February 4, 2027, and the remaining shares vest in 36 equal monthly installments afterward, as long as the CFO continues to provide service through each vesting date.
IN8bio, Inc. reported an equity award to its President and COO, Kate Rochlin, on a Form 4. On February 4, 2026, she received an employee stock option covering 80,000 shares of common stock at an exercise price of $1.96 per share, held directly.
The option expires on February 4, 2036. Vesting is time-based: 25% of the option vests on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on her continued service with the company.
IN8bio, Inc. (INAB) reported a new stock option grant to CEO, director and 10% owner William Tai-Wei Ho. On February 4, 2026, he received an employee stock option covering 206,000 shares of common stock at an exercise price of $1.96 per share, expiring February 4, 2036.
According to the vesting terms, 25% of the option shares vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues to provide service through each vesting date. Following this grant, he beneficially owns 206,000 derivative securities directly.